Serplulimab is an anti-PD-1 immunosuppressive antineoplastic agent. It is primarily indicated for patients with advanced solid tumors confirmed by specific genetic testing, especially those with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) tumors.
The drug must be used strictly under medical supervision, and the final patient eligibility should be determined based on individual disease conditions and clinical evaluation.
Indicated Patient Populations & Criteria
1. Patients with MSI-H/dMMR Advanced Solid Tumors
Indicated for patients with solid tumors (including colorectal cancer, gastric cancer, endometrial cancer, etc.) confirmed as MSI-H or dMMR by tissue or blood testing,
who have experienced disease progression after prior systemic therapy or have no other effective treatment options.
2. Patients with Non-Small Cell Lung Cancer (NSCLC)
For first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer without driver gene mutations (e.g., EGFR, ALK wild-type), used in combination with chemotherapy.
3. Other Patients Eligible per Clinical Evaluation
Clinical trials have suggested potential efficacy of serplulimab in esophageal carcinoma, squamous cell carcinoma of the head and neck, and other tumor types.
Use in these settings requires comprehensive assessment of tumor type, genetic profile, and prior treatment history.
Important Safety & Usage Information
Medical Supervision
Prescribed only after evaluation by an oncologist. Dosage is determined based on body weight, body surface area, etc. Do not adjust or discontinue treatment without medical advice.
Contraindications & Precautions
Contraindicated in patients with hypersensitivity to any ingredient of the product. Patients with active severe autoimmune diseases or organ transplant recipients should be contraindicated or use with caution.
Monitoring for Adverse Reactions
May cause immune-related adverse events including pneumonitis, colitis, hepatitis, etc. Regular monitoring of liver function, thyroid function, and other laboratory tests is required. Seek medical attention promptly for any abnormal findings.
Treatment Evaluation
During treatment, efficacy should be assessed regularly via imaging and hematological examinations. Discontinue or modify treatment if disease progresses or unacceptable toxicity occurs.
If you meet the above conditions, please bring complete medical records to an oncology clinic for an individualized treatment plan.
